iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Gland Pharma’s net profit increases by more than 100% to Rs 192.4 crore in March quarter

23 May 2024 , 12:30 PM

Gland Pharma, a Hyderabad-based drugmaker owned by China’s Fosun Pharma, more than doubled its net profit to ₹192.4 Crore in Q4FY24, boosted by a rebound in the US, Europe, and other regulated markets, despite operational challenges at its acquired contract development and manufacturing organisation (CDMO) business in Europe.

The company declared its first post-listing dividend of ₹20 per equity share in FY24. Gland Pharma earned a net profit of ₹78.7 Crore in the same period the previous year.

In the fourth quarter of FY24, revenue from operations increased to ₹1,537.5 Crore. The earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 113% year on year (YoY) to ₹358.7 Crore. In the fourth quarter of FY24, the EBITDA margin increased by 200 basis points year on year to 23%.

The net profit and EBITDA margin excluding ex-Cenexi, a contract manufacturing firm that Gland acquired for more than ₹1,000 Crore early last year, were three times higher, at ₹316 Crore and 34%, respectively.

Gland stated that Cenexi sales decreased in Q4FY24 principally due to operational delays, breakdowns that resulted in substantial order backlogs, and delayed tech transfer.

Despite difficulties in realising the full potential of the transaction, Gland remains bullish on Cenexi’s medium- to long-term prospects.

Gland’s revenue increased 56% to ₹5,665 Crore in FY24, while its net profit fell 1% to ₹772.5 Crore. The EBITDA margin fell 400 basis points to 24%.

The US business rose 83% year on year to ₹878.4 Crore, while the Cenexi purchase aided Europe in posting a seven-fold sales increase of ₹268.5 Crore. Canada, Australia, and New Zealand increased 58% to ₹57.8 Crore, while India decreased 19% to ₹52.6 Crore. The rest of the world (RoW) sales increased by 64% to ₹280 Crore.

At around 11.25 AM, Gland Pharma was trading 4.92% higher at ₹1,881.20 per share, against the previous close of ₹1,793.05 on NSE. The counter touched an intraday high and low of ₹1,989.90, and ₹1,861.20, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

Related Tags

  • Gland Pharma
  • Gland Pharma Earnings
  • Gland Pharma news
  • Gland Pharma Q4
  • Gland Pharma Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.